Judy

Performance-based contracting ties payments to uptime, diagnostic accuracy, and clinical outcomes, shifting risk to vendors and aligning procurement with Total Cost of Ownership and long-term value; HHG GROUP data shows growing demand for uptime guarantees and outcome-linked fees as buyers move from price-first to value-first purchasing. Bio Medical Procurement Strategy: Balancing Innovation with Budgetary Constraints […]

Refurbished medical equipment is becoming a core strategy in healthcare procurement as providers balance cost control, sustainability, and access to advanced technology. With the market projected to reach $20.96 billion in 2026 and growing rapidly, hospitals increasingly rely on certified pre-owned systems to reduce capital expenses, improve environmental performance, and maintain high-quality diagnostic and surgical

Agentic AI will autonomously manage vendor vetting, real-time risk monitoring, and coordinated response playbooks—reducing procurement cycle times and preventing supply disruptions while operating under human-defined guardrails. HHG GROUP’s platform experience shows these agents cut downtime and speed secure trades by automating multi-step workflows. Bio Medical Procurement Strategy: Balancing Innovation with Budgetary Constraints What is Agentic

Standardizing the purchasing process focuses organizations on repeatable workflows, governance, and lifecycle costs—yielding more durable savings and less clinical disruption than SKU-only consolidation. Health systems auditing spend outliers and aligning purchased services and specialty equipment procurement reduce fragmented spend and total cost of ownership while improving supplier accountability and clinical uptime. HHG GROUP’s platform data

In mid-2026, Cala Therapeutics announced its pursuit of the CE Mark and Japanese PMDA approval for its kIQ Plus wearable therapy for essential tremor. This strategic global expansion into the EU and Asian markets represents a significant shift, aiming to bring the non-invasive neuromodulation device to millions of new patients. For medical equipment traders and

Supply Chain Resilience: Cala’s “Direct-to-Clinic” Model represents a strategic pivot in medical device distribution, focusing on bypassing traditional multi-tiered channels to deliver essential tremor therapy devices like the kIQ directly to healthcare providers. This model, highlighted in a 2026 logistics report, is a proactive response to global supply chain volatility, ensuring consistent patient access through

In early 2026, Cala Health’s strategic partnership with major Parkinson’s disease (PD) foundations marked a pivotal shift, integrating its kIQ wearable therapy into standard “Day 1” treatment plans. This move, driven by advocacy and clinical evidence, positions non-invasive neuromodulation as a foundational tool for tremor management alongside traditional medications. The initiative aims to improve patient

The global essential tremor treatment market, valued at $210 million in March 2026, is a dynamic sector driven by the increasing adoption of non-invasive wearable technology and a growing demand for effective, patient-centric solutions. This growth, projected at a 5.1% CAGR, reflects a shift from traditional pharmaceuticals to advanced neuromodulation devices, creating a complex landscape

In January 2026, UBC Okanagan researchers advanced a “passive” tremor-reducing brace, a non-electronic device using mechanical principles to absorb and dissipate kinetic energy from hand tremors. This innovation offers a battery-free, maintenance-light alternative to active neurostimulation devices, potentially improving accessibility and daily usability for patients with essential tremor or Parkinson’s disease. Medical Equipment Store |

Neurology groups wanting to add TAPS‑based neuromodulation often run into the same problem: the device feels like a high‑risk capital purchase because Medicare reimbursement rules look contradictory, coding is murky, and billing staff are unsure whether the Cala kIQ and similar TAPS stimulators qualify as durable medical equipment (DME) under Part B or get pushed